The Magazine for Sleep Professionals
Monday, September 21, 2026
Vivos Therapeutics, Inc. announced it has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA […]
ProSomnus, Inc. has announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are also participating in the financing. A description of the terms of the offering can […]
ProSomnus, Inc. announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HGNS) in treating patients with severe OSA. The clinical trial plans follow updated results from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT), a prospective, independent, head-to-head, crossover […]
ProSomnus, Inc. released the results of a survey conducted in partnership with Prodege, a cutting-edge consumer marketing and insights platform, on the major obstacles to identifying and treating snoring and OSA, including a lack of awareness of where to seek medical advice. Key findings of the survey of 1,000 people […]
ProSomnus, Inc. announced the presentation of four abstracts at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held May 19-21 in Philadelphia, Pennsylvania, and two abstracts at the American Thoracic Society (ATS) 2023 International Conference, held May 19-24 in Washington, D.C. The data presented at both meetings […]
ProSomnus, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has allowed a patent application covering the Company’s proprietary automated manufacturing process for the Company’s precision medical devices; this is the third patent to issue in this family, including already-issued USPN 10,213,280 and USPN 9,808,327. ProSomnus’s intellectual property […]
By Ashley Spooner, DDS, D.ABDSM Introduction: Undiagnosed and untreated sleep apnea is a serious and growing health problem. The adult population in the United States has a prevalence of obstructive sleep apnea (OSA) of 12%.1 This prevalence is rising at an estimated 14% growth rate between 2022-2027 due to factors […]
Panthera Dental has received notification from the Pricing, Data Analysis and Coding (PDAC) contractor, following their request for a coding decision for the Panthera D-SAD Classic oral appliance. PDAC, following a formal review and assessment, has classified the HCPCS code (Healthcare Common Procedure Coding System) E0486 to be used when […]
By Jason Tierney What goes bump in the night can result in significant pain in the daytime. New research has been published demonstrating the effectiveness of the Nociceptive Trigeminal Inhibition Tension Suppression System, or NTI-tss Plus, in significantly reducing medically diagnosed migraine pain. The device is worn during sleep and […]
ProSomnus, a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of three studies evaluating its FDA-cleared Oral Appliance Therapy (OAT) devices in the treatment of OSA. ProSomnus will share data in three poster presentations at SLEEP 2022, the Annual Meeting of […]
